MediPharm Achieves Key Milestone Toward $4.5 Million Cash Sale of Hope Facility, On Track to Close in June
TORONTO, May 22, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the removal of all conditions precedent, related to its previously-announced agreement (the 'Purchase Agreement') for the sale of MediPharm's facility in Hope, BC, ('Hope Facility') to Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) for $4.5 million in cash (the 'Transaction').
With these conditions now met, the $4.5 million sale of the Hope Facility remains on track to close in June 2025. The Transaction will bolster MediPharm's already strong cash position and virtually debt-free financial status.
David Pidduck, CEO of MediPharm commented, 'The $4.5 million in cash proceeds from divesting non-core assets supports our roadmap to deliver long-term value for shareholders and partners, enabling continued focus on accelerating international growth and exploration of key acquisition opportunities.'
The Hope Facility was acquired as part of the successful VIVO Cannabis Inc. acquisition in 2023, and the Company ceased all Hope Facility commercial activities in 2024, consolidating key operations at its other facilities. The consolidation of operations was all part of MediPharm's ongoing strategy to reduce operating and overhead costs and monetize redundant assets. The aggregate value of the Company's asset sales since 2022, including the Hope Facility, total approximately $14 million, all of which has contributed to reducing costs and boosting the Company's balance sheet.
Since the second quarter of 2022, when implementation of this strategy began, to the first quarter of 2025, MediPharm has reduced operating and overhead costs by approximately $42 million dollars on an annualized basis.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA.
In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical Australia PTY Ltd. and Beacon Medical Germany GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions.
The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.
Investor Contact:
MediPharm Labs Investor RelationsTelephone: +1 416.913.7425Email: investors@medipharmlabs.com
Media Contact:
John VincicOakstrom Advisors+1 (647) 402-6375john@oakstrom.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things: timing for the closing of the Transaction, impacts of the Transaction to the Company's cash position and financial status, plans for long-term value for shareholders and partners, acceleration of international growth and acquisition opportunities, future reduction of the Company's costs, and future impacts of the Transaction to the Company's balance sheet. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs' continuous disclosure filings, available on the SEDAR+ website at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
64552143.2
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Vizsla Royalties Announces Completion of Payment of Acquisition and Amendment to Compensation Plan
Vancouver, British Columbia--(Newsfile Corp. - June 13, 2025) - Vizsla Royalties Corp. (TSXV: VROY) (OTCQB: VROYF) ("Vizsla Royalties" or the "Company") is pleased to announce an update regarding its acquisition of an additional 3.0% net smelter returns royalty on certain concessions comprising the Panuco-Copala Silver-Gold Project located in the State of Sinaloa, Mexico (the "Transaction"). Further to its news release dated June 12, 2025, the funds comprising the purchase price have been released to the vendor and the Transaction is formally complete. The Company has also amended its omnibus equity incentive compensation plan (the "Omnibus Plan"), that was originally adopted by the Company's board of directors on April 1, 2025, to increase the fixed amount in additional equity that includes performance share units, deferred share units and restricted share units from a maximum issuable of 2,800,589 to a maximum issuable of 5,322,798. The purpose of the Omnibus Plan is to: (i) promote a significant alignment between officers, directors, and employees of the Company and the growth objectives of the Company; (ii) to associate a portion of participating employees' compensation with the performance of the Company over the long term; and (iii) to attract, motivate and retain the critical employees to drive the business success of the Company. Pursuant to the terms of the Omnibus Plan, the Company has granted 3,961,850 stock options ("Options") at an exercise price of $2.35 and, 2,522,780 restricted share units (each, an "RSU") to directors, officers, employees and consultants (the "Optionees") of the Company. The Options are exercisable for a period of five years and will vest over the next two years and the RSUs will vest in three equal annual instalments commencing on the first anniversary of the grant date. The Omnibus Plan and all issuances granted under the Omnibus Plan are subject to approval of the TSX Venture Exchange and disinterested shareholder approval. These approvals will be sought at the Company's next annual general meeting to be held in Q3 2025. About Vizsla Royalties Corp. Vizsla Royalties Corp. is a precious metals focused royalty company. The Company's principal asset is a Net Smelter Return Royalty on Vizsla Silver Corp.'s (TSX: VZLA) (NYSE American: VZLA) flagship Panuco Project located in Mexico. Panuco is a world-class silver and gold development project actively advancing towards production. A Preliminary Economic Study for Panuco was published in July 2024 which highlights 15.2 Moz AgEq of annual production over an initial 10.6-year mine life, an after-tax NPV5% of US$1.1B, 86% IRR and a 9-month payback at US$26/oz Ag and US$1,975/oz Au. Contact Information: For more information and to sign-up to the mailing list, please contact: Michael Pettingell, Chief Executive Officer Tel: (604) 364-2215 Email: info@ Website: Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. TECHNICAL AND THIRD-PARTY INFORMATION Except where otherwise stated, the disclosure in this press release relating to the Panuco Project is based on information publicly disclosed by Vizsla Silver Corp. and information/data available in the public domain as at the date hereof and none of this information has been independently verified by Vizsla Royalties. Specifically, as a royalty holder, Vizsla Royalties has limited access to the Panuco Project. Although Vizsla Royalties does not have any knowledge that such information may not be accurate, there can be no assurance that such third-party information is complete or accurate. Some information publicly reported on the Panuco Project by Vizsla Silver Corp. may relate to a larger property than the area covered by Vizsla Royalties' royalty interests. Unless otherwise indicated, the technical and scientific disclosure contained or referenced in this press release, including any references to mineral resources or mineral reserves, was prepared in accordance with NI 43-101, which differs significantly from the requirements of the U.S. Securities and Exchange Commission (the "SEC") applicable to U.S. domestic issuers. Accordingly, the scientific and technical information contained or referenced in this press release may not be comparable to similar information made public by U.S. companies subject to the reporting and disclosure requirements of the SEC. "Inferred mineral resources" have a great amount of uncertainty as to their existence and great uncertainty as to their economic and legal feasibility. It cannot be assumed that all or any part of an inferred mineral resource will ever be upgraded to a higher category. Historical results or feasibility models presented herein are not guarantees or expectations of future performance. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable securities laws. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budgets", "scheduled", "estimates", "forecasts", "predicts", "projects", "intends", "targets", "aims", "anticipates" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements include, but are not limited to:the closing of the Transaction; the use of proceeds from the Offering; the final approval of the TSXV; future exploration, development, and production of the Panuco Project, and other anticipated developments, achievements and economics of, the Panuco Project. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties, and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of Vizsla Royalties to control or predict, that may cause Vizsla Royalties' actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including but not limited to: risks associated with the impact of general business and economic conditions; the absence of control over mining operations from which Vizsla Royalties will purchase precious metals or from which it will receive stream or royalty payments and risks related to those mining operations, including risks related to international operations, government and environmental regulation, delays in mine construction and operations, actual results of mining and current exploration activities, conclusions of economic evaluations and changes in project parameters as plans are refined; problems related to the ability to market precious metals or other metals; industry conditions, including commodity price fluctuations, interest and exchange rate fluctuations; interpretation by government entities of tax laws or the implementation of new tax laws; regulatory, political or economic developments in any of the countries where properties in which Vizsla Royalties holds a royalty, stream or other interest are located or through which they are held; risks related to the operators of the properties in which Vizsla Royalties holds a royalty or stream or other interest, including changes in the ownership and control of such operators; risks related to global pandemics and the spread of other viruses or pathogens; influence of macroeconomic developments; business opportunities that become available to, or are pursued by Vizsla Royalties; reduced access to debt and equity capital; litigation; title, permit or license disputes related to interests on any of the properties in which Vizsla Royalties holds a royalty, stream or other interest; the volatility of the stock market; competition; future sales or issuances of debt or equity securities; use of proceeds; dividend policy and future payment of dividends; liquidity; market for securities; enforcement of civil judgments; and risks relating to Vizsla Royalties potentially being a passive foreign investment company within the meaning of U.S. federal tax laws; and the other risks and uncertainties disclosed in documents filed with or submitted to the Canadian securities regulatory authorities on the SEDAR+ website at Although Vizsla Royalties has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Vizsla Royalties undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information. To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
8 minutes ago
- Yahoo
Charlotte's Web Reports Shareholder Meeting Voting Results
LOUISEVILLE, Colo., June 13, 2025 /CNW/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") is pleased to announce the results from its 2025 annual general meeting of shareholders held on June 12, 2025 via live audio webcast (the "Meeting"). Each of the matters voted upon at the Meeting is discussed in detail in the Company's Proxy Statement dated April 29, 2025, a copy of which is available on the Company's SEDAR profile at and on EDGAR at The total number of votes cast at the Meeting was 58,493,957, representing 36.87% of the total number of votes attached to the outstanding voting shares of the Company. According to the proxies received, the results of the vote for the election of directors were as follows: Nominee # Votes For % Votes For # Votes Withheld % Votes Withheld Jonathan Atwood 10,483,075 72 % 4,120,698 28 % Matthew McCarthy 11,896,877 82 % 2,706,896 18 % Angela McElwee 11,902,297 82 % 2,701,476 18 % William Morachnick 10,490,456 72 % 4,113,317 28 % Jared Stanley 9,676,914 66 % 4,926,859 34 % Maureen Usifer 12,639,816 87 % 1,963,957 13 % Detailed results of the matters considered at the Meeting are reported in the Report of Voting Results as filed on the Company's SEDAR+ profile at About Charlotte's Web Holdings, Inc. Charlotte's Web Holdings, Inc., a Certified B Corporation headquartered in Louisville, Colorado, is a botanical wellness innovation company and a market leader in hemp extract wellness that includes Charlotte's Web whole-plant full-spectrum CBD extracts as well as broad-spectrum CBD and cannabinoid isolates. The Company's hemp extracts have naturally occurring botanical compounds including cannabidiol ("CBD"), CBN, CBC, CBG, THC, terpenes, flavonoids, and other beneficial compounds. Charlotte's Web product categories include CBD oil tinctures (liquid products), CBD gummies (sleep, calming, exercise recovery, immunity), CBN gummies, hemp-derived THC microdose gummies, functional mushroom gummies, CBD capsules, CBD topical creams, and lotions, as well as CBD pet products for dogs. Through its substantially vertically integrated business model, Charlotte's Web maintains stringent control over product quality and consistency with analytic testing from soil to shelf for quality assurance. Charlotte's Web products are distributed to retailers and healthcare practitioners throughout the U.S.A. and are available online through the Company's website at View original content to download multimedia: SOURCE Charlotte's Web Holdings, Inc. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Orezone Announces Results of Meeting of Shareholders
VANCOUVER, British Columbia, June 13, 2025 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the 'Company' or 'Orezone') reports that all resolutions from the Company's annual general and special meeting of shareholders held on June 12, 2025 (the 'Meeting') were approved with 62.76% of the total issued and outstanding shares of the Company represented at the Meeting. Detailed voting results for the election of directors are as follows: Nominee For % For Against % Against Julian Babarczy 311,422,274 99.63% 1,143,461 0.37% Joe Conway 307,958,117 98.53% 4,607,618 1.47% Patrick Downey 311,751,459 99.74% 814,276 0.26% Rob Doyle 312,507,445 99.98% 58,290 0.02% Kate Harcourt 312,332,268 99.93% 233,467 0.07% Sean Harvey 312,155,498 99.87% 410,237 0.13% Tara Hassan 312,008,591 99.82% 557,144 0.18% Additional matters approved at the Meeting are as follows: The number of directors was fixed at seven. The Company's stock option plan, as required by the TSX every three years, was reapproved. Deloitte LLP was appointed as auditors for the fiscal year ending December 31, 2025, and the board of directors was authorized to fix their remuneration. The 'Report of Voting Results', which is available under the Company's profile on SEDAR+ and on the Company's website, discloses the detailed voting results for the above resolutions. For additional details, please also see the Management Information Circular of the Company dated May 9, 2025. About Orezone Gold Corporation Orezone Gold Corporation (TSX: ORE OTCQX: ORZCF) is a West African gold producer engaged in mining, developing, and exploring its 90%-owned flagship Bomboré Gold Mine in Burkina Faso. The Bomboré mine achieved commercial production on its oxide operations on December 1, 2022, and is now focused on its staged hard rock expansion that is expected to materially increase annual and life-of-mine gold production from the processing of hard rock mineral reserves. Orezone is led by an experienced team focused on social responsibility and sustainability with a proven track record in project construction and operations, financings, capital markets, and M&A. The technical report entitled Bomboré Phase II Expansion, Definitive Feasibility Study is available on SEDAR+ and the Company's website. Contact Information Patrick DowneyPresident and Chief Executive Officer Kevin MacKenzieVice President, Corporate Development and Investor Relations Tel: 1 778 945 8977 info@ / For further information please contact Orezone at +1 (778) 945 8977 or visit the Company's website at The Toronto Stock Exchange neither approves nor disapproves the information contained in this news release.
